Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ligand Pharmaceuticals (LGND) Research & Development (2016 - 2025)

Ligand Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $3.5 million for Q4 2025.

  • For Q4 2025, Research & Development fell 20.66% year-over-year to $3.5 million; the TTM value through Dec 2025 reached $81.2 million, up 278.91%, while the annual FY2025 figure was $81.2 million, 278.91% up from the prior year.
  • Research & Development for Q4 2025 was $3.5 million at Ligand Pharmaceuticals, down from $21.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $50.1 million in Q1 2025 and bottomed at $3.5 million in Q4 2025.
  • The 5-year median for Research & Development is $7.1 million (2021), against an average of $9.8 million.
  • The largest annual shift saw Research & Development tumbled 42.19% in 2021 before it soared 738.8% in 2025.
  • A 5-year view of Research & Development shows it stood at $8.1 million in 2021, then increased by 12.89% to $9.2 million in 2022, then crashed by 40.33% to $5.5 million in 2023, then decreased by 19.37% to $4.4 million in 2024, then dropped by 20.66% to $3.5 million in 2025.
  • Per Business Quant, the three most recent readings for LGND's Research & Development are $3.5 million (Q4 2025), $21.0 million (Q3 2025), and $6.6 million (Q2 2025).